Patents themselves should not be seen as ‘rights’ (IPR), but rather as a tool with which to incentivize innovation in the sectors where they are relevant–but in such a way that the public sector also gets its return; drug prices could become ‘fairer’, reflecting the collective contribution of different actors and making a healthcare system sustainable.
